Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По годам
Ettinghausen SE, Rosenberg SA.
Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.Cancer Res. 1986 Jun;46(6):2784-92. PMID: 3486038.
Harel-Bellan A, Bertoglio J, Quillet A et al.
Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.J Immunol. 1986 Apr 1;136(7):2463-9. PMID: 3005412.
Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.Cancer Res. 1986 Feb;46(2):676-83. PMID: 3484431.
Mulé JJ, Yang J, Shu S, Rosenberg SA.
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.J Immunol. 1986 May 15;136(10):3899-909. PMID: 2871106.
Oshimi K., Oshimi Y., Akutsu M. et al.
Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.Blood (1986) 68 (4): 938-948.
Papa MZ, Mulé JJ, Rosenberg SA.
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.Cancer Res. 1986 Oct;46(10):4973-8. PMID: 3489517.
Thurman GB, Maluish AE, Rossio JL et al.
Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations.J Biol Response Mod. 1986 Feb;5(1):85-107. PMID: 3514800.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.